Compare IFBD & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IFBD | ALZN |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 9.0M |
| IPO Year | 2021 | 2021 |
| Metric | IFBD | ALZN |
|---|---|---|
| Price | $0.98 | $2.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $42.00 |
| AVG Volume (30 Days) | 19.5K | ★ 97.7K |
| Earning Date | 01-01-0001 | 12-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,861,442.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1520.48 | N/A |
| 52 Week Low | $0.88 | $1.88 |
| 52 Week High | $2.70 | $12.06 |
| Indicator | IFBD | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 46.29 | 46.65 |
| Support Level | $0.92 | $2.09 |
| Resistance Level | $1.05 | $2.27 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 32.20 | 61.70 |
Infobird Co Ltd is engaged in developing and providing customer engagement cloud-based services. It software-as-a-service provider of AI-powered, or artificial intelligence-enabled, customer engagement solutions in China. It provides holistic software solutions to help corporate clients proactively deliver and manage end-to-end customer engagement activities at all stages of the sales process, including pre-sales and sales activities, and post-sales customer support. It also offers AI-powered cloud-based sales force management software, including intelligent quality inspection and intelligent training software to help clients monitor, benchmark, and improve the performance of agents.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.